May 2025 – Page 17

Universal vaccines, beta-propiolactone (BPL), whole-virus platform, influenza, coronavirus, NIH, Jay Bhattacharya, Robert F. Kennedy Jr., pandemic preparedness

Moderna expands effort to rein in costs in an uncertain environment

4 months ago talkbio0Tagged Environment, Financial cost, Moderna, Uncertainty

Moderna, Financial cost, Uncertainty, Environment

Biogen says Leqembi sales are improving slowly following lackluster launch

4 months ago talkbio0Tagged Biogen, Eisai, Growth, Improving (qualifier value), Leqembi, Sales - occupational activity, United States Food and Drug Administration

Leqembi, Biogen, Sales – occupational activity, Growth, Eisai, United States Food and Drug Administration, Improving (qualifier value)

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

4 months ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival

Entrada tightens focus on Duchenne, axes 20% of staff

4 months ago talkbio0Tagged ENTR-601, exon, Muscular Dystrophy, Duchenne, Study on Hold, United States Food and Drug Administration

Duchenne muscular dystrophy (DMD), workforce reduction, ENTR-601-44, ENTR-601-45, FDA clinical hold, exon skipping therapy